Register Login
Register to leave comments
  • News bot Jan. 29, 2026, 8:11 p.m.

    📋 Castle Biosciences Inc (CSTL) - Clinical Trial Update

    Filing Date: 2026-01-13

    Accepted: 2026-01-13 09:43:02

    Event Type: Clinical Trial Update

    Event Details:

    Castle Biosciences Inc (CSTL) Announces Clinical Trial Update Castle Biosciences Inc (CSTL) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: opportunities, reports
    • Diseases/Conditions: our core revenue drivers (DecisionDx®-Melanoma
    • Collaboration: DecisionDx®-Melanoma
    • Updated Timeline: 2024Year-end, the fourth quarter and year ended Dec. 31, 2025

    🔬 Clinical Development Pipeline (Castle Biosciences Inc):

    Product Type Development Stage Therapeutic Area Source
    Placebo BIOLOGICAL Phase PHASE2 Restrictive Burn Scars of Joint Area ClinicalTrials.gov
    Autologous Human Fibroblasts (Isolagen TherapyTM) BIOLOGICAL Phase PHASE2 Restrictive Burn Scars of Joint Area ClinicalTrials.gov
    Autologous Human Fibroblasts (azficel-T) BIOLOGICAL Phase PHASE3 Bilateral Nasolabial Fold Wrinkles ClinicalTrials.gov
    Autologous Human Fibroblast (azficel-T) BIOLOGICAL Phase PHASE3 Bilateral Nasolabial Fold Wrinkles ClinicalTrials.gov
    Azficel-T (autologous fibroblasts) BIOLOGICAL Phase PHASE2 Dysphonia Resulting From Vocal Fold Scarring ClinicalTrials.gov
    placebo sterile saline BIOLOGICAL Phase PHASE2 Restrictive Burn Scars ClinicalTrials.gov
    Autologous fibroblasts BIOLOGICAL Phase PHASE2 Restrictive Burn Scars ClinicalTrials.gov
    FCX-007 GENETIC Phase PHASE1 Epidermolysis Bullosa Dystrophica, Recessive ClinicalTrials.gov
    veledimex DRUG Phase PHASE1 Morphea ClinicalTrials.gov
    FCX-013 GENETIC Phase PHASE1 Morphea ClinicalTrials.gov
    180 mg controlled release form DRUG Phase PHASE1 Healthy ClinicalTrials.gov
    90 mg controlled release form DRUG Phase PHASE1 Healthy ClinicalTrials.gov
    Ecopipam immediate release form DRUG Phase PHASE1 Healthy ClinicalTrials.gov
    Ecopipam DRUG Phase PHASE3 Lesch-Nyhan Disease ClinicalTrials.gov
    FCX-007 (dabocemagene autoficel; see below for FCX-007 description) BIOLOGICAL Phase PHASE3 Recessive Dystrophic Epidermolysis Bullosa ClinicalTrials.gov
    D-Fi BIOLOGICAL Phase PHASE3 Dystrophic Epidermolysis Bullosa ClinicalTrials.gov
    ecopipam HCl ~2mg/kg/day DRUG Preclinical Tourettes Disorder ClinicalTrials.gov

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition
    • Licensing: Not available
    • Regulatory Approval: Not available
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Castle Biosciences Inc
    • Ticker Symbol: CSTL

Search

News categories